Search | Page 4 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab

    ... Journal Title:  Blood Primary Author:  ... During the study, six patients received at least one red blood cell transfusion . Lack of detectable CH50 activity (defined by ...

    Research Article last updated 01/20/2015 - 2:28pm.

  2. Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide.

    ... Five of these patients had an ongoing requirement for red blood cell transfusions despite previous treatment with recombinant ...

    Research Article last updated 10/11/2011 - 5:58pm.

  3. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

    ... Journal Title:  Blood Primary Author:  ... cytogenetics , presence of circulating blasts, and red blood cell transfusion dependency ≥ 4 units/8 weeks (all P < 10(-4)) ...

    Research Article last updated 07/28/2014 - 8:53am.

  4. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

    ... Overall Response (complete or partial remission, red blood cell [RBC] or platelet transfusion independence [TI], or ...

    Research Article last updated 12/09/2015 - 8:56am.

  5. Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes

    ... catheter placement (ORadj=6.47, 95% CI: 2.37, 17.62) and red blood cell transfusion (ORadj=4.60, 95% CI: 2.29, 9.23) were associated ...

    Research Article last updated 12/05/2011 - 10:09am.

  6. Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes

    ... Journal Title:  J Blood Med Primary Author:  ... of patients with del(5q) MDS, including reduction in red blood cell transfusion requirements and improvements in quality of ...

    Research Article last updated 03/02/2015 - 2:11pm.

  7. Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study

    ... dependency (defined as having received at least one red blood cell transfusion every 8 weeks over a period of 4 months), Eastern ...

    Research Article last updated 11/10/2015 - 10:47am.

  8. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes

    ... that lenalidomide is effective not only in reducing red blood cell (RBC) transfusion burden, but also in modifying the disease ...

    Research Article last updated 12/08/2015 - 1:06pm.

  9. Myelodysplastic syndromes and the role of iron overload.

    ... in patients with MDS due to the long-term use of red blood cell transfusions in patients with symptomatic anemia . ...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study

    ... mg at 16 weeks, respectively. RESULTS: Rates of red blood cell - transfusion independence (RBC-TI) ≥182 days were ...

    Research Article last updated 07/29/2014 - 12:12pm.